Androgenic Alopecia as a Predictive Factor for Benign Prostatic Hyperplasia

    January 2018 in “ Universidad Privada Antenor Orrego
    Alegre Yataco, Paola Stephanie
    Image of study
    TLDR Male pattern baldness may be an early sign of noncancerous prostate enlargement.
    The study conducted five years ago aimed to determine if androgenic alopecia (male pattern baldness) could be a predictor of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland. The retrospective case-control study involved 128 patients, split evenly into two groups. The average age was 67.53 ± 8.68 years and 65.11 ± 9.72 years, respectively. The mean prostatic volume in the case group was significantly larger (71.1406 ± 3.32 cm3) than the control group (17.30 ± 4.72 cm3). The study found a significant association between androgenic alopecia and BPH (p <0.05), with an odds ratio of 4.56. Additionally, androgenic alopecia and arterial hypertension were identified as factors related to BPH. The study concluded that androgenic alopecia could be an early marker of BPH.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Male pattern baldness, and mental health

      in Finasteride/Dutasteride  325 upvotes 10 months ago
      A 48-year-old man has been using minoxidil for 15 years and considered finasteride but stopped due to potential side effects. He is concerned about his mental health and the impact of hair loss on self-image, and he encourages support among men experiencing hair loss.

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 1 year ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

      community My mum is mad annoying about Fin.

      in Chat  245 upvotes 7 months ago
      A 25-year-old man discusses his struggles with his mother's opposition to his use of Finasteride for hair loss treatment, despite it improving his condition and self-control after a hair transplant. He expresses frustration over her blaming the medication for various issues and the stress caused by her insistence to stop taking it.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Similar Research

    6 / 1000+ results